307 related articles for article (PubMed ID: 25791169)
1. Non-sirtuin histone deacetylases in the control of cardiac aging.
Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
[TBL] [Abstract][Full Text] [Related]
2. CaMKII exacerbates heart failure progression by activating class I HDACs.
Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Demos-Davies KM; Ferguson BS; Cavasin MA; Mahaffey JH; Williams SM; Spiltoir JI; Schuetze KB; Horn TR; Chen B; Ferrara C; Scellini B; Piroddi N; Tesi C; Poggesi C; Jeong MY; McKinsey TA
Am J Physiol Heart Circ Physiol; 2014 Jul; 307(2):H252-8. PubMed ID: 24858848
[TBL] [Abstract][Full Text] [Related]
4. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.
Schuetze KB; McKinsey TA; Long CS
J Mol Cell Cardiol; 2014 May; 70():100-7. PubMed ID: 24631770
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Raghunathan S; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases in cardiovascular and metabolic diseases.
Bagchi RA; Weeks KL
J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
[TBL] [Abstract][Full Text] [Related]
7. The biology and therapeutic implications of HDACs in the heart.
McKinsey TA
Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
[TBL] [Abstract][Full Text] [Related]
8. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Kee HJ; Kook H
J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
[TBL] [Abstract][Full Text] [Related]
9. Chromatin modifications remodel cardiac gene expression.
Mathiyalagan P; Keating ST; Du XJ; El-Osta A
Cardiovasc Res; 2014 Jul; 103(1):7-16. PubMed ID: 24812277
[TBL] [Abstract][Full Text] [Related]
10. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Lemon DD; Horn TR; Cavasin MA; Jeong MY; Haubold KW; Long CS; Irwin DC; McCune SA; Chung E; Leinwand LA; McKinsey TA
J Mol Cell Cardiol; 2011 Jul; 51(1):41-50. PubMed ID: 21539845
[TBL] [Abstract][Full Text] [Related]
11. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
12. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
13. Role of HDACs in cardiac electropathology: Therapeutic implications for atrial fibrillation.
Brundel BJJM; Li J; Zhang D
Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118459. PubMed ID: 30880147
[TBL] [Abstract][Full Text] [Related]
14. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.
Zhang CL; McKinsey TA; Chang S; Antos CL; Hill JA; Olson EN
Cell; 2002 Aug; 110(4):479-88. PubMed ID: 12202037
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases: salesmen and customers in the post-translational modification market.
Brandl A; Heinzel T; Krämer OH
Biol Cell; 2009 Apr; 101(4):193-205. PubMed ID: 19207105
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase 3 (HDAC3)-dependent Reversible Lysine Acetylation of Cardiac Myosin Heavy Chain Isoforms Modulates Their Enzymatic and Motor Activity.
Samant SA; Pillai VB; Sundaresan NR; Shroff SG; Gupta MP
J Biol Chem; 2015 Jun; 290(25):15559-15569. PubMed ID: 25911107
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
18. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.
Habibian J; Ferguson BS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597863
[TBL] [Abstract][Full Text] [Related]
19. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
McKinsey TA
J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs.
McClure JJ; Inks ES; Zhang C; Peterson YK; Li J; Chundru K; Lee B; Buchanan A; Miao S; Chou CJ
ACS Chem Biol; 2017 Jun; 12(6):1644-1655. PubMed ID: 28459537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
